Gonca Kılıç Yıldırım

Dr. Gonca Kılıç Yıldırım

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
MDMeltem Dinleyici
Meltem Dinleyici
Yvan VandenplasYvan Vandenplas
Yvan Vandenplas
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
Introduction: Gut microbiota manipulation may be a potential therapeutic target to reduce host energy storage. There is limited information about the effects of probiotics/synbiotics on intestinal microbiota composition in children and adolescents with obesity. The objective of this randomized double-blind placebo-controlled trial was to test the effects of a multispecies synbiotic on intestinal microbiota composition in children and adolescents with exogenous obesity. Method: Children with exogenous obesity were managed with a standard diet and increased physical activity and were randomly allocated into two groups at a ratio of 1:1; the 1st group received synbiotic supplementation (probiotic mixture including Lactobacillus acidophilus, Lacticaseibacillus. rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 × 109 CFU/sachet) and fructo-oligosaccharides (FOS; 625 mg/sachet) for 12 weeks; the 2nd group received placebo once daily for 12 weeks. Fecal samples were obtained before and at the end of the 12-week intervention to characterize the changes in the gut microbiota composition. Detailed metagenomic and bioinformatics analyses were performed. Results: Before the intervention, there were no significant differences in alpha diversity indicators between the synbiotic and placebo groups. After 12 weeks of intervention, the observed taxonomic units and Chao 1 were lower in the synbiotic group than at baseline (p < 0.001 for both). No difference for alpha diversity indicators was observed in the placebo group between baseline and 12 weeks of intervention. At the phylum level, the intestinal microbiota composition of the study groups was similar at baseline. The major phyla in the synbiotic group were Firmicutes (66.7%) and Bacteroidetes (18.8%). In the synbiotic group, the Bacteroidetes phylum was higher after 12 weeks than at baseline (24.0% vs. 18.8%, p < 0.01). In the synbiotic group, the Firmicutes/Bacteroidetes ratio was 3.54 at baseline and 2.75 at 12 weeks of intervention (p < 0.05). In the placebo group, the Firmicutes/Bacteroidetes ratio was 4.70 at baseline and 3.54 at 12 weeks of intervention (p < 0.05). After 12 weeks of intervention, the Firmicutes/Bacteroidetes ratio was also lower in the synbiotic group than in the placebo group (p < 0.05). In the synbiotic group, compared with the baseline, we observed a statistically significant increase in the genera Prevotella (5.28–14.4%, p < 0.001) and Dialister (9.68–13.4%; p < 0.05). Compared to baseline, we observed a statistically significant increase in the genera Prevotella (6.4–12.4%, p < 0.01) and Oscillospira (4.95% vs. 5.70%, p < 0.001) in the placebo group. In the synbiotic group, at the end of the intervention, an increase in Prevotella, Coprococcus, Lachnospiraceae (at the genus level) and Prevotella copri, Coprococcus eutactus, Ruminococcus spp. at the species level compared to baseline (predominance of Eubacterium dolichum, Lactobacillus ruminis, Clostridium ramosum, Bulleidia moorei) was observed. At the end of the 12th week of the study, when the synbiotic and placebo groups were compared, Bacteroides eggerthi species were dominant in the placebo group, while Collinsella stercoris species were dominant in the synbiotic group. Conclusion: This study is the first pediatric obesity study to show that a synbiotic treatment is associated with both changes intestinal microbiota composition and decreases in BMI. Trial identifier: NCT05162209 (www.clinicaltrials.gov).

1 January 2022 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
KCKursat Bora Carman
Kursat Bora Carman
KAKursad Aydın
Kursad Aydın
BKBetül Kılıç
Betül Kılıç
ACAli Cansu
Ali Cansu
MDMeltem Cobanogullari Direk
Meltem Cobanogullari Direk
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım

11 March 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
PKPelin Teke Kısa
Pelin Teke Kısa
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
BHBurcu Ozturk Hismi
Burcu Ozturk Hismi
SYSevil Yıldız
Sevil Yıldız
ÖKÖzge Küsbeci
Özge Küsbeci
NANur Arslan
Nur Arslan

27 October 2022 in Life
Verified
Journal Article
Open access
PDF file
Berna Seker YilmazBerna Seker Yilmaz
Berna Seker Yilmaz
JBJ. Baruteau
J. Baruteau
NANur Arslan
Nur Arslan
HAHalil Ibrahim Aydin
Halil Ibrahim Aydin
MBMagalie Barth
Magalie Barth
Paul GissenPaul Gissen
Paul Gissen
X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. We audited the diagnosis and management of OTCD, using an online 12-question-survey that was sent to 75 metabolic centres in Turkey, France and the UK. Thirty-nine centres responded and 495 patients were reported in total. A total of 208 French patients were reported, including 71 (34%) males, 86 (41%) symptomatic and 51 (25%) asymptomatic females. Eighty-five Turkish patients included 32 (38%) males, 39 (46%) symptomatic and 14 (16%) asymptomatic females. Out of the 202 UK patients, 66 (33%) were male, 83 (41%) asymptomatic and 53 (26%) symptomatic females. A total of 19%, 12% and 7% of the patients presented with a neonatal-onset phenotype in France, Turkey and the UK, respectively. Vomiting, altered mental status and encephalopathy were the most common initial symptoms in all three countries. While 69% in France and 79% in Turkey were receiving protein restriction, 42% were on a protein-restricted diet in the UK. A total of 76%, 47% and 33% of patients were treated with ammonia scavengers in Turkey, France and the UK, respectively. The findings of our audit emphasize the differences and similarities in manifestations and management practices in three countries.

1 May 2019 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
YKYeter Düzenli Kar
Yeter Düzenli Kar
ZÖZeynep C. Özdemir
Zeynep C. Özdemir
EKEylem Kiral
Eylem Kiral
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
ÖBÖzcan Bör
Özcan Bör
Background: Hemophagocytic lymphohystiocytosis (HLH) is characterized by fever, splenomegaly, pancytopenia, and elevated levels of triglycerides and ferritin. These signs and symptoms are common to other metabolic diseases. Observation: A 5-month-old female infant, who presented with fever, respiratory distress, massive hepatomegaly, and bicytopenia, was diagnosed as having HLH and chemotherapy was initiated. The patient was negative for familial HLH gene mutations. Respiratory distress and laboratory findings improved rapidly after starting chemotherapy. However, there was no improvement in the massive hepatomegaly and she experienced hypoglycemic episodes. In addition, her family history included a cousin with glycogen storage disease (GSD). On the basis of the findings, the patient was diagnosed as having type Ia GSD. There are no previous reports of HLH secondary to GSD type Ia in the literature. Conclusions: Congenital metabolic diseases should be considered in the differential diagnosis of children with HLH.

31 January 2022 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
PAPelin Asfuroglu
Pelin Asfuroglu
AAAyse Tana Aslan
Ayse Tana Aslan
AAAyse Tana Aslan
Ayse Tana Aslan
TGTugba Ramasli Gursoy
Tugba Ramasli Gursoy
NENagehan Emiralioglu
Nagehan Emiralioglu
DDDeniz Dogru
Deniz Dogru